Effective October 11, 2022 (Effective Date), Thomas Hallam, Ph.D., the Chief Executive Officer and a member of the Board of Directors (Board) of Palisade Bio, Inc. and its wholly owned subsidiary, Leading Biosciences, Inc. resigned as both Chief Executive Officer and as a member of the Board, of both entities to pursue other opportunities. As of the Effective Date, J.D. Finley, the Company's current Chief Financial Officer, was appointed by the Board to serve as the Company's Chief Executive Officer (principal executive officer), on an interim basis. Mr. Finley will additionally continue to serve as the Company's Chief Financial Officer and principal accounting officer.

J.D. Finley, age 65, has served as the Company's Chief Financial Officer since April 2021. Previously, Mr. Finley served as Leading Biosciences, Inc's (the Company's wholly owned subsidiary and predecessor company) Chief Financial Officer since January 2017 and as a member of board of directors of Leading Biosciences, Inc. (the “LBS Board”) since December 2014. Prior to joining Leading Biosciences, Inc., Mr. Finley was Chief Executive Officer of PointAcross, Inc., a marketing company, from January 2016 to January 2017.

Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses, and was CFO at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. From March 2011 to June 2012 Mr. Finley was Executive Vice President, and from June 2012 to April 2014, Mr. Finley was President of Goldmail. Mr. Finley received a B.A. in business administration from Boise State University and an M.S. in Taxation from the University of Denver.